you are here: Home News Halol

Halol

USFDA pulls up Sun Pharma for lapses in Halol plant
FDA's warning letter points to cGMP violations at Halol facility: Sun Pharma
Sun Pharma: Strong speciality show, scale-up in clinical trials awaited
US FDA flags quality lapses at Sun Pharma's Gujarat plant: Report
Sun Pharma: Traction in speciality likely to sustain
Sun Pharma: Sustained traction in speciality to be a re-rating driver
Sun Pharma’s steady India business and US speciality portfolio should help it do well in FY22
Analysts retain buy on Sun Pharma as USFDA clears Mohali, Halol unit resolution key
Here are Sanjiv Bhasin's top trading ideas
Sun Pharma up 3% as co may shift key products from Halol plant
Nifty on Cloud Nine! 9 stocks with a high margin of safety
USFDA report on Halol unit to be positive in long-term: Sun
Do not see any urgency to buy Sun Pharma, says Dipan Mehta
Sun Pharma rebounds, Halol unit observations not worrisome
Sun Pharma up 2% as USFDA issues 9 observations for Halol unit
Sun Pharma down 6% on 14-page USFDA observations letter to Halol
Sun Pharma falls 7%, sector under pressure on US probe fear
Sun Pharma Q1 net seen at Rs 1894 cr, US sales likely at $598 mn
Hero MotoCorp inks 3-year wage agreement with Gurgaon workers
Sun Pharma falls 6% on weak sales guidance, price pressure woes
Analysts bet psoriasis drug to aid Sun Pharma's US kitty
LM Power commissions second manufacturing facility in India
Export weakness, Chinese truck radials dumping a worry: Ceat
Sun Pharma to ask FDA in Q1 FY17 for Halol re-inspection
Sun Pharma Q3 profit seen up 4.4%, Gleevec & Halol key

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Halol

USFDA pulls up Sun Pharma for lapses in Halol plant

FDA's warning letter points to cGMP violations at Halol facility: Sun Pharma

Sun Pharma: Strong speciality show, scale-up in clinical trials awaited

US FDA flags quality lapses at Sun Pharma's Gujarat plant: Report

Sun Pharma: Traction in speciality likely to sustain

Sun Pharma: Sustained traction in speciality to be a re-rating driver

Sun Pharma’s steady India business and US speciality portfolio should help it do well in FY22

Analysts retain buy on Sun Pharma as USFDA clears Mohali, Halol unit resolution key

Here are Sanjiv Bhasin's top trading ideas

Sun Pharma up 3% as co may shift key products from Halol plant

Nifty on Cloud Nine! 9 stocks with a high margin of safety

USFDA report on Halol unit to be positive in long-term: Sun

Do not see any urgency to buy Sun Pharma, says Dipan Mehta

Sun Pharma rebounds, Halol unit observations not worrisome

Sun Pharma up 2% as USFDA issues 9 observations for Halol unit

Sun Pharma down 6% on 14-page USFDA observations letter to Halol

Sun Pharma falls 7%, sector under pressure on US probe fear

Sun Pharma Q1 net seen at Rs 1894 cr, US sales likely at $598 mn

Hero MotoCorp inks 3-year wage agreement with Gurgaon workers

Sun Pharma falls 6% on weak sales guidance, price pressure woes

Analysts bet psoriasis drug to aid Sun Pharma's US kitty

LM Power commissions second manufacturing facility in India

Export weakness, Chinese truck radials dumping a worry: Ceat

Sun Pharma to ask FDA in Q1 FY17 for Halol re-inspection

Sun Pharma Q3 profit seen up 4.4%, Gleevec & Halol key